These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27579324)

  • 1. Potential of IL-33 for Preventing the Kidney Injury via Regulating the Lipid Metabolism in Gout Patients.
    Duan L; Huang Y; Su Q; Lin Q; Liu W; Luo J; Yu B; He Y; Qian H; Liu Y; Chen J; Shi G
    J Diabetes Res; 2016; 2016():1028401. PubMed ID: 27579324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Soluble C-X-C chemokine ligand 16 levels are increased in gout patients.
    Gong Q; Wu F; Pan X; Yu J; Li Y; Lu T; Li X; Lin Z
    Clin Biochem; 2012 Nov; 45(16-17):1368-73. PubMed ID: 22627199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hypertension, renal function and gout.
    Gibson T; Highton J; Simmonds HA; Potter CF
    Postgrad Med J; 1979; 55 Suppl 3():21-5. PubMed ID: 504036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diuretic induced gout: a multifactorial condition.
    Scott JT; Higgens CS
    Ann Rheum Dis; 1992 Feb; 51(2):259-61. PubMed ID: 1550414
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Central arterial characteristics of gout patients with chronic kidney diseases.
    Celik G; Yilmaz S; Kebapcilar L; Gundogdu A
    Int J Rheum Dis; 2017 May; 20(5):628-638. PubMed ID: 26176346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protective effect of the standardized extract of ginkgo biloba (EGb761) against hypertension with hypercholesterolemia-induced renal injury in rats: Insights in the underlying mechanisms.
    Abdel-Zaher AO; Farghaly HSM; El-Refaiy AEM; Abd-Eldayem AM
    Biomed Pharmacother; 2017 Nov; 95():944-955. PubMed ID: 28915536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipid studies in primary gout.
    Yu TF; Oreskes I
    Mt Sinai J Med; 1989 Jan; 56(1):11-6. PubMed ID: 2784177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impaired renal function gout: its association with hypertensive vascular disease and intrinsic renal disease.
    Yü TF; Berger L
    Am J Med; 1982 Jan; 72(1):95-100. PubMed ID: 7058827
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Renal function and lipid metabolism in pregnant renal transplant recipients.
    Czajkowski K; Wójcicka-Bentyn J; Sieńko J; Grymowicz M; Smolarczyk R; Malinowska-Polubiec A; Romejko E
    Eur J Obstet Gynecol Reprod Biol; 2004 Jun; 114(2):155-61. PubMed ID: 15140508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical characteristics of and relationship between metabolic components and renal function among patients with early-onset juvenile tophaceous gout.
    Lu CC; Wu SK; Chen HY; Chung WS; Lee MC; Yeh CJ
    J Rheumatol; 2014 Sep; 41(9):1878-83. PubMed ID: 25086077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of longitudinal changes in serum uric acid levels and associated risk of cardio-metabolic events and renal function decline in gout.
    Desai RJ; Franklin JM; Spoendlin-Allen J; Solomon DH; Danaei G; Kim SC
    PLoS One; 2018; 13(2):e0193622. PubMed ID: 29489919
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renal function in gout patients.
    Tarng DC; Lin HY; Shyong ML; Wang JS; Yang WC; Huang TP
    Am J Nephrol; 1995; 15(1):31-7. PubMed ID: 7872362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Not all inflammatory markers are linked to kidney function: results from a population-based study.
    Pruijm M; Ponte B; Vollenweider P; Mooser V; Paccaud F; Waeber G; Marques-Vidal P; Burnier M; Bochud M
    Am J Nephrol; 2012; 35(3):288-94. PubMed ID: 22398717
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of lead in gout nephropathy.
    Batuman V; Maesaka JK; Haddad B; Tepper E; Landy E; Wedeen RP
    N Engl J Med; 1981 Feb; 304(9):520-3. PubMed ID: 6779160
    [No Abstract]   [Full Text] [Related]  

  • 15. IL-33 and ST2 levels in chronic kidney disease: Associations with inflammation, vascular abnormalities, cardiovascular events, and survival.
    Gungor O; Unal HU; Guclu A; Gezer M; Eyileten T; Guzel FB; Altunoren O; Erken E; Oguz Y; Kocyigit I; Yilmaz MI
    PLoS One; 2017; 12(6):e0178939. PubMed ID: 28614418
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radiographic bone damage in chronic gout is negatively associated with the inflammatory cytokines soluble interleukin 6 receptor and osteoprotegerin.
    Choe JY; Lee GH; Kim SK
    J Rheumatol; 2011 Mar; 38(3):485-91. PubMed ID: 21159831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Hyperlipoproteinemia in primary gout and asymptomatic hyperuricemia].
    Kullich W; Ulreich A; Klein G
    Wien Med Wochenschr; 1988 May; 138(10):221-5. PubMed ID: 3407202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fenofibrate increases serum creatinine in a patient with familial nephropathy associated to hyperuricemia.
    Salgueiro G; Beltrán LM; Torres RJ; Puig JG
    Nucleosides Nucleotides Nucleic Acids; 2014; 33(4-6):181-4. PubMed ID: 24940667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The impact of Ramadan fast on patients with gout.
    Habib G; Badarny S; Khreish M; Khazin F; Shehadeh V; Hakim G; Artul S
    J Clin Rheumatol; 2014 Oct; 20(7):353-6. PubMed ID: 25275760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gout and its relation to lipid metabolism. I. Serum uric acid, lipid, and lipoprotein levels in gout.
    Mielants H; Veys EM; de Weerdt A
    Ann Rheum Dis; 1973 Nov; 32(6):501-5. PubMed ID: 4357330
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.